Candel Therapeutics, Inc. (CADL) Dividend History

Company News

• Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

  Candel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.

  GlobeNewswire Inc.
• Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

  Candel Therapeutics, a clinical-stage biopharmaceutical company, has appointed Elizabeth M. Jaffee, M.D., a renowned expert in pancreatic cancer and immunology, to its Research Advisory Board. This appointment aligns with Candel's focus on developing multimodal biological immunotherapies for cancer treatment, particularly in borderline resectable pancreatic cancer.

  GlobeNewswire Inc.
• Candel Therapeutics Announces $80 Million Proposed Public Offering

  Candel Therapeutics, a clinical-stage biopharmaceutical company, announced the launch of an $80 million public offering of its common stock and pre-funded warrants. The company plans to use the proceeds to continue the development of its product candidates, including preparing the submission of a Biologics License Application for CAN-2409 in prostate cancer.

  GlobeNewswire Inc.
• Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

  Milestone Pharmaceuticals announced the appointment of Joseph Papa, a renowned pharmaceutical and healthcare leader, to its Board of Directors. Papa's extensive experience in the industry is expected to provide strategic guidance as Milestone prepares for the potential approval of its investigational drug CARDAMYST for the treatment of paroxysmal supraventricular tachycardia.

  GlobeNewswire Inc.

  Featured Companies: BLCO EBS MIST PRGO
• Candel Therapeutics executive sells over $63k in company stock - Investing.com

  Candel Therapeutics' Interim Chief Financial Officer Charles Schoch sold over $63,000 worth of company stock to cover tax withholding obligations related to the vesting of restricted stock units. The transaction indicates continued investment in the company's future.

  Investing.com